Fig. 6. Results of flow cytometry-based assay of MAPK and PI3K pathway activation of WM266-4 cells in presence of 2155-14. (A). 24 h treatment with 100 μM 2155-14. (B) 48 h treatment with 100 μM 2155-14. One-way analysis of variance (ANOVA) was used followed by Dunnett post hoc test. The data shown were the mean ± SD, n=3. ***** - p<0.0001, ns - no significance; 2155-14 Trametinib/dabrafenib combination was tested at 25 µM of each compound. MAPK+PI3K inactive - cell population with neither MAPK nor PI3K pathway activated; MAPK only active - cell population with just MAPK pathway activated; MAPK+PI3K active - cell population with both MAPK and PI3K pathways activated; PI3K only active - cell population with just PI3K pathway activated.